Online citations, reference lists, and bibliographies.
← Back to Search

Phenytoin Carried By Silica Core Iron Oxide Nanoparticles Reduces The Expression Of Pharmacoresistant Seizures In Rats.

Argelia Rosillo-de la Torre, Lizbeth Zurita-Olvera, S. Orozco-Suárez, Perla E. García Casillas, H. Salgado-Ceballos, G. Luna-Bárcenas, Luisa Rocha
Published 2015 · Medicine, Materials Science
Referenced 2 times by Citationsy Users

Cite This
Download PDF
Analyze on Scholarcy
Share
AIM The present study was focused to evaluate the anticonvulsant effects of phenytoin (PHT) loaded in the silica core of iron oxide nanoparticles (NPs) in an animal model with pharmacoresistant seizures. MATERIALS & METHODS PHT-loaded NPs were synthesized and characterized. The anticonvulsant effects of PHT-loaded NPs were investigated in rats with pharmacoresistant seizures associated with brain P-glycoprotein (P-gp) overexpression. RESULTS & CONCLUSION In P-gp-overexpressing rats, administration of PHT-loaded NPs resulted in reduced prevalence of clonus (40% p < 0.05) and tonic-clonic seizures (20%; p < 0.02). These effects were not evident when animals were treated with PHT not loaded in the NPs. The results obtained support the notion that NPs can be used as drugs carriers to the brain with pharmacoresistant seizures.
This paper references
10.1016/S1525-5050(03)00111-2
The impact of epilepsy on quality of life: a qualitative analysis
M. Bishop (2003)
10.1016/S1474-4422(11)70193-4
Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials
P. Ryvlin (2011)
Neuromodulation advances for seizure control. In: Topics in Neuromodulation Treatment
A Velasco (2012)
10.1016/S0513-5117(08)70031-0
Cognitive Prognosis in Chronic Temporal Lobe Epilepsy
J. C. DeToledo (2007)
10.1016/j.jocn.2011.03.043
Refractory epilepsy and deep brain stimulation
E. Pereira (2012)
10.1212/WNL.51.1.48
Vagus nerve stimulation therapy for partial-onset seizures
A. Handforth (1998)
10.1124/jpet.107.132225
The Role of ATP Binding Cassette Transporters in Tissue Defense and Organ Regeneration
M. Huls (2009)
10.1016/J.IJPHARM.2005.10.010
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.
Donald E. Owens (2006)
10.3109/21691401.2014.998832
Magnetic nanoparticles as potential candidates for biomedical and biological applications
Fatemeh Zeinali Sehrig (2016)
10.1016/S0920-1211(02)00156-0
Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy
U. Seegers (2002)
10.1186/1476-511X-11-72
Formulation and evaluation of chitosan solid lipid nanoparticles of carbamazepine
Rahul S. Nair (2012)
10.5772/52115
Magnetic Nanoparticles: Synthesis, Surface Modifications and Application in Drug Delivery
S. Bucak (2012)
10.1016/J.YNEU.2010.12.020
Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies
M. Brodie (2011)
10.1016/j.neulet.2006.11.075
Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model
C. Höcht (2007)
10.1023/B:CEMN.0000012726.43842.d2
Neuronal and Glial Expression of the Multidrug Resistance Gene Product in an Experimental Epilepsy Model
A. Lazarowski (2004)
Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study.
E. Okon (1994)
10.1093/BRAIN/AWH437
Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures.
H. Volk (2005)
10.1182/BLOOD.V41.4.529.529
The role of the sinus wall in the passage of erythrocytes through the spleen.
L. Chen (1973)
10.1016/J.CERAMINT.2010.09.010
Morphological studies of randomized dispersion magnetite nanoclusters coated with silica
Choon Yian Haw (2011)
10.1016/j.brainres.2009.09.039
Thyrotropin-releasing hormone d,l polylactide nanoparticles (TRH-NPs) protect against glutamate toxicity in vitro and kindling development in vivo
Michael C. Veronesi (2009)
10.1016/S0304-3940(02)00423-8
P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood–brain barrier: evidence from microdialysis experiments in rats
H. Potschka (2002)
10.1016/J.MATCHAR.2006.11.006
Characterization of sodium phenytoin co-gelled with titania for a controlled drug-release system
T. López (2007)
10.1186/1556-276X-7-210
Preparation of hollow magnetite microspheres and their applications as drugs carriers
F. Márquez (2012)
10.1016/J.COLSURFA.2005.04.009
Investigation of formation of silica-coated magnetite nanoparticles via sol–gel approach
Yonghui Deng (2005)
10.1038/nbt1340
Renal clearance of quantum dots
H. Choi (2007)
10.1038/nrc706
Multidrug resistance in cancer: role of ATP–dependent transporters
M. Gottesman (2002)
10.1016/j.nurt.2009.02.001
Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles
M. Kubek (2011)
10.1016/c2009-0-63235-9
The Rat Brain in Stereotaxic Coordinates
G. Paxinos (1983)
10.1002/JPS.20935
Formulation of spray-dried phenytoin loaded poly(epsilon-caprolactone) microcarrier intended for brain delivery to treat epilepsy.
Zhuzhu Li (2007)
Treatment-resistant schizophrenia: reviewing the options and identifying the way forward.
J. Hellewell (1999)
10.1109/INEC.2010.5425143
Preparation and magnetic properties of magnetite nanoparticles by sol-gel method
Hongzhang Qi (2010)
10.1124/jpet.106.101154
A Mechanistic Study of Enhanced Doxorubicin Uptake and Retention in Multidrug Resistant Breast Cancer Cells Using a Polymer-Lipid Hybrid Nanoparticle System
H. L. Wong (2006)
10.1039/c2cs15308d
Functionalized mesoporous silica materials for controlled drug delivery.
P. Yang (2012)
10.1016/J.NANTOD.2011.10.001
Toxicology and clinical potential of nanoparticles
L. Yildirimer (2011)
10.1016/S1525-5050(02)00511-5
P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice
G. Sills (2002)
10.1002/jps.24044
Nanoparticle formulation improves the anticonvulsant effect of clonazepam on the pentylenetetrazole-induced seizures: behavior and electroencephalogram.
G. Leyva-Gómez (2014)
10.1016/j.jconrel.2011.01.024
Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro.
Forrest M Kievit (2011)
10.1016/J.COLSURFA.2011.03.042
Controlled release of IFC-305 encapsulated in silica nanoparticles for liver cancer synthesized by sol–gel
León Albarran (2011)
10.1016/J.MATLET.2011.09.116
Preparation and magnetic properties of magnetite nanoparticles
F. Zhao (2012)
Preparation of biocompatible magnetitecarboxymethyl cellulose nanocomposite: characterization of nanocomposite by FTIR, XRD, FESEM and TEM. Spectrochim
N. Habibi (2014)
10.1073/PNAS.91.9.3497
Cell biological mechanisms of multidrug resistance in tumors.
S. Simon (1994)
10.1002/ADFM.200700093
Poly(vinyl alcohol) Scaffolds with Tailored Morphologies for Drug Delivery and Controlled Release
M. Gutiérrez (2007)
10.1016/j.ncl.2009.06.001
Identification of pharmacoresistant epilepsy.
A. Berg (2009)
10.2478/s11532-010-0073-4
Effect of the polymeric coating over Fe3O4 particles used for magnetic separation
Raúl Terrazas Reza (2010)
10.1016/j.neuroimage.2012.01.048
Imaging seizure-induced inflammation using an antibody targeted iron oxide contrast agent
Ben A. Duffy (2012)
10.1212/01.CON.0000431397.61970.2b
Neurostimulation for Drug-Resistant Epilepsy
C. DeGiorgio (2013)
10.2147/IJN.S24309
A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin
J. Cheng (2011)
10.1093/TOXSCI/KFJ027
Toxicity and tissue distribution of magnetic nanoparticles in mice.
J. Kim (2006)
10.1016/S0193-953X(05)70283-5
Definition and epidemiology of treatment-resistant depression.
M. Fava (1996)
10.1016/J.PHYSE.2011.10.015
Effect of pH, citrate treatment and silane-coupling agent concentration on the magnetic, structural and surface properties of functionalized silica-coated iron oxide nanocomposite particles
H. Mohammad-Beigi (2011)
10.1111/j.1365-2990.2004.00557.x
Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours
E. Neuwelt (2004)
10.3797/scipharm.1109-03
Validated HPLC Method for Concurrent Determination of Antipyrine, Carbamazepine, Furosemide and Phenytoin and its Application in Assessment of Drug Permeability through Caco-2 Cell Monolayers
S. Patil (2012)
10.1021/mp7001285
Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats.
Tapan Jain (2008)
10.1056/NEJM199603073341008
Surgery for seizures.
J. Engel (1996)
10.5772/29261
Neuromodulation Advances for Seizure Control
Ana Luisa Velasco (2012)
10.1016/j.pharep.2014.06.007
Chronic administration of phenytoin induces efflux transporter overexpression in rats.
Silvana Alvariza (2014)
10.1016/j.saa.2014.04.039
Preparation of biocompatible magnetite-carboxymethyl cellulose nanocomposite: characterization of nanocomposite by FTIR, XRD, FESEM and TEM.
N. Habibi (2014)
10.1161/STROKEAHA.107.481788
Iron Oxide Particle-Enhanced MRI Suggests Variability of Brain Inflammation at Early Stages After Ischemic Stroke
A. Saleh (2007)
10.1002/CHIN.200924219
Magnetic Iron Oxide Nanoparticles: Synthesis and Surface Functionalization Strategies
W. Wu (2009)
10.1016/j.nbd.2006.06.014
The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy
C. Brandt (2006)
10.1007/978-1-59745-294-6_2
Processing biological tissues for ultrastructural study.
J. A. Mascorro (2007)
10.1002/ANA.410200202
Phenytoin: Mechanisms of its anticonvulsant action
Y. Yaari (1986)
10.2147/IJN.S15881
Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model
S. Eskandari (2011)
10.1016/j.neuro.2012.09.006
Neurotoxic potential of iron oxide nanoparticles in the rat brain striatum and hippocampus.
J. Wu (2013)
10.1016/S0939-6411(99)00073-9
Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system.
A. Friese (2000)
10.1590/S0366-69132009000400013
Synthesis and characterization of magnetic nanoparticles coated with silica through a sol-gel approach
Â. L. Andrade (2009)
10.1016/j.jconrel.2014.05.029
Sustained-release from nanocarriers: a review.
Jayaganesh V. Natarajan (2014)
10.2147/IJN.S34588
Plausible antioxidant biomechanics and anticonvulsant pharmacological activity of brain-targeted β-carotene nanoparticles
Mohammad Yusuf (2012)
10.1016/S0927-7757(02)00305-9
Preparation and characterization of magnetite nanoparticles coated by amino silane
M. Ma (2003)
10.5698/1535-7511-12.5.188
Neurostimulation—Past, Present, and Beyond
E. Ben-Menachem (2012)
10.1016/J.APSUSC.2008.09.071
Preparation and characterization of silica-coated Fe3O4 nanoparticles used as precursor of ferrofluids
R. Y. Hong (2009)
10.1016/J.JCONREL.2005.05.024
In vitro degradation and controlled release behavior of D,L-PLGA50 and PCL-b-D,L-PLGA50 copolymer microspheres.
Chang-Ming Dong (2005)
10.1002/0470846356.CH4
Drug resistance in epilepsy: the role of the blood-brain barrier.
N. Abbott (2002)
10.1111/j.0013-9580.2004.03104.x
Brain Blood‐flow Alterations Induced by Therapeutic Vagus Nerve Stimulation in Partial Epilepsy: II. Prolonged Effects at High and Low Levels of Stimulation
T. Henry (2004)
10.1097/00006123-199608000-00061
Vagus nerve stimulation activates central nervous system structures in epileptic patients during PET H2(15)O blood flow imaging.
D. Ko (1996)
10.1081/DDC-120001481
Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
P. Lockman (2002)
10.1002/CHIN.201231267
Functionalized Mesoporous Silica Materials for Controlled Drug Delivery
P. Yang (2012)
10.1039/c4nr05061d
Size dependent biodistribution and toxicokinetics of iron oxide magnetic nanoparticles in mice.
L. Yang (2015)
10.1016/j.jconrel.2012.05.038
Design and characterization of a novel amphiphilic chitosan nanocapsule-based thermo-gelling biogel with sustained in vivo release of the hydrophilic anti-epilepsy drug ethosuximide.
Meng-Hsuan Hsiao (2012)
Swelling controlled release systems; progress toward zero-order kinetics with polymer blends
RW Korsemeyer (1982)
10.2147/IJN.S596
Drug delivery and nanoparticles: Applications and hazards
W. D. de Jong (2008)
10.1111/j.1528-1157.1995.tb01657.x
MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy
D. M. Tishler (1995)
10.1111/j.1528-1167.2010.02585.x
Modulating P‐glycoprotein regulation: Future perspectives for pharmacoresistant epilepsies?
H. Potschka (2010)
10.1088/0957-4484/19/41/415101
Bio-functionalization of magnetite nanoparticles using an aminophosphonic acid coupling agent: new, ultradispersed, iron-oxide folate nanoconjugates for cancer-specific targeting.
M. Das (2008)
10.1016/S1748-0132(07)70084-1
Magnetic nanoparticles for drug delivery
M. Arruebo (2007)
10.4236/SNL.2011.12005
Synthesis and Characterization of Monodisperse Magnetite Hollow Microspheres
Marquez Francisco (2011)
10.1111/j.1471-4159.1974.tb04401.x
PROPERTIES OF BRAIN l‐GLUTAMATE DECARBOXYLASE: INHIBITION STUDIES 1
J. Wu (1974)
Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing
G. Scherer (1990)
10.1523/JNEUROSCI.22-14-05833.2002
Limbic Seizures Induce P-Glycoprotein in Rodent Brain: Functional Implications for Pharmacoresistance
M. Rizzi (2002)
10.1111/j.1528-1167.2008.01615.x
Functionalized magnetonanoparticles for MRI diagnosis and localization in epilepsy
Massoud Akhtari (2008)
10.1111/j.1528-1167.2010.02536.x
Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy
R. Fisher (2010)
10.1111/j.1528-1167.2006.00496.x
Inhibition of the Multidrug Transporter P‐Glycoprotein Improves Seizure Control in Phenytoin‐treated Chronic Epileptic Rats
E. V. van Vliet (2006)
10.2165/11209880-000000000-00000
Ferumoxytol: in iron deficiency anaemia in adults with chronic kidney disease.
P. L. McCormack (2012)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar